Related Experiment Video
Updated: Aug 19, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Antibiotics needed to treat multidrug-resistant infections in neonates
Phoebe Cm Williams1, Shamim A Qazi2, Ramesh Agarwal3
1School of Public Health, Faculty of Medicine, Edward Ford Building, The University of Sydney, Camperdown, NSW, 2006, Australia.
Insights
Neonatal infections are a major cause of death, with limited antibiotic options for drug-resistant strains. Developing a priority list for neonatal antibiotics is crucial to accelerate research and reduce infant mortality.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Neonatal infections are a primary cause of mortality globally.
- Antimicrobial resistance (AMR) and a sparse antibiotic pipeline hinder effective neonatal treatment.
- Few antibiotics approved for adults include neonatal dosing, highlighting a critical research gap.
Approach:
- Review the World Health Organization (WHO) priority pathogens list for neonatal sepsis.
- Propose a WHO multiexpert stakeholder meeting to establish a neonatal priority antibiotic development list.
- Advocate for an international, interdisciplinary consensus to accelerate neonatal antibiotic development.
Key Points:
- Only 4 of 40 antibiotics approved since 2000 include neonatal dosing.
- Adult antibiotic trials significantly outnumber neonatal trials (43 vs. 6).
- Addressing AMR in neonates requires a focused, accelerated development program.
Conclusions:
- A dedicated neonatal antibiotic development program is essential.
- Prioritizing specific antibiotics for neonates will streamline research efforts.
- Reducing morbidity and mortality from multidrug-resistant infections in neonates is achievable through focused international collaboration.
Abstract:
Infections remain a leading cause of death in neonates. The sparse antibiotic development pipeline and challenges in conducting neonatal research have resulted in few effective antibiotics being adequately studied to treat multidrug-resistant (MDR) infections in neonates, despite the increasing global mortality burden caused by antimicrobial resistance. Of 40 antibiotics approved for use in adults since 2000, only four have included dosing information for neonates in their labelling. Currently, 43 adult antibiotic clinical trials are recruiting patients, compared with only six trials recruiting neonates. We review the World Health Organization (WHO) priority pathogens list relevant to neonatal sepsis and propose a WHO multiexpert stakeholder meeting to promote the development of a neonatal priority antibiotic development list. The goal is to develop international, interdisciplinary consensus for an accelerated neonatal antibiotic development programme. This programme would enable focused research on identified priority antibiotics for neonates to reduce the excess morbidity and mortality caused by MDR infections in this vulnerable population.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of Antibiotic Resistance
Antibiotic Selection
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

